We are live on ! Find out more
ELI

ELITE PHARMACEUTICAL
ELI

Delisted

ELI was delisted on the 20th of May, 2009.

Back to rankings

5 hedge funds and large institutions have $138K invested in ELITE PHARMACEUTICAL in 2016 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more funds holding

Funds holding: 4 → 5 (+1)

6% more capital invested

Capital invested by funds: $130K → $138K (+$7.9K)

Holders
5
Holders Change
+1
Holders Change %
+25%
% of All Funds
0.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VWM
Valley Wealth Managers
New Jersey
+$2K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
GA
1
Geneva Advisors
Illinois
$95K – – –
JAFL
2
Jay A. Fishman Ltd
Michigan
$19.5K – – –
SBL
3
Sargent Bickham Lagudis
Colorado
$13K – – –
PCA
4
Personal Capital Advisors
California
$8K – – –
VWM
5
Valley Wealth Managers
New Jersey
$2K +$2K +7,500 New

ELI Hedge Fund Activity: Q2 2016 in Review

5 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in ELITE PHARMACEUTICAL (ELI) for Q2 2016, worth a combined $138K — up 6.1% from $130K a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new ELI positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Valley Wealth Managers, opening a new position worth an estimated $2K.

  • 5 institutional investors held ELITE PHARMACEUTICAL (ELI) as of Q2 2016, up from 4 in Q1 2016.
  • Funds reported $138K of ELITE PHARMACEUTICAL stock for Q2 2016, up 6.1% quarter-over-quarter.
  • 1 fund opened new ELITE PHARMACEUTICAL positions in Q2 2016 and 0 closed out, a net change of +1 holder.
  • The largest ELITE PHARMACEUTICAL buyer in Q2 2016 was Valley Wealth Managers, an estimated $2K added.

Based on aggregated 13F filings for Q2 2016.